Westpac Banking Corp’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.3M Buy
2,614
+85
+3% +$37.7K 0.08% 194
2026
Q1
$1.13M Sell
2,529
-76
-3% -$35.4K 0.08% 194
2025
Q4
$1.18M Buy
2,605
+131
+5% +$56.5K 0.07% 206
2025
Q3
$969K Sell
2,474
-271
-10% -$113K 0.06% 218
2025
Q2
$1.22M Buy
2,745
+72
+3% +$33.2K 0.08% 198
2025
Q1
$1.3M Sell
2,673
-609
-19% -$284K 0.1% 200
2024
Q4
$1.32M Sell
3,282
-124
-4% -$57.5K 0.09% 201
2024
Q3
$1.58M Buy
3,406
+128
+4% +$61.5K 0.11% 184
2024
Q2
$1.54M Buy
3,278
+381
+13% +$165K 0.12% 157
2024
Q1
$1.21M Sell
2,897
-659
-19% -$279K 0.09% 189
2023
Q4
$1.45M Buy
3,556
+83
+2% +$30.7K 0.12% 171
2023
Q3
$1.21M Sell
3,473
-3,076
-47% -$1.08M 0.09% 205
2023
Q2
$2.3M Sell
6,549
-38,130
-85% -$12.8M 0.16% 167
2023
Q1
$14.1M Sell
44,679
-5,349
-11% -$1.6M 0.19% 139
2022
Q4
$14.4M Buy
50,028
+13,809
+38% +$4.21M 0.21% 126
2022
Q3
$10.5M Sell
36,219
-3,850
-10% -$1.11M 0.16% 168
2022
Q2
$11.3M Sell
40,069
-1,502
-4% -$402K 0.15% 184
2022
Q1
$10.8M Buy
41,571
+15,571
+60% +$3.7M 0.12% 225
2021
Q4
$5.71M Sell
26,000
-73
-0.3% -$14.2K 0.06% 382
2021
Q3
$4.73M Sell
26,073
-42,566
-62% -$8.31M 0.05% 428
2021
Q2
$13.8M Buy
68,639
+4,542
+7% +$950K 0.14% 179
2021
Q1
$13.8M Buy
64,097
+359
+0.6% +$78.9K 0.15% 169
2020
Q4
$15.1M Buy
63,738
+27,140
+74% +$6.23M 0.17% 146
2020
Q3
$9.96M Buy
36,598
+3,285
+10% +$906K 0.13% 188
2020
Q2
$9.67M Sell
33,313
-5,899
-15% -$1.6M 0.14% 179
2020
Q1
$9.33M Buy
39,212
+14,704
+60% +$3.37M 0.16% 168
2019
Q4
$5.37M Buy
24,508
+2,116
+9% +$428K 0.07% 371
2019
Q3
$3.79M Hold
22,392
0.05% 422
2019
Q2
$4.11M Sell
22,392
-47,461
-68% -$8.3M 0.06% 347
2019
Q1
$12.8M Sell
69,853
-37,819
-35% -$6.99M 0.21% 132
2018
Q4
$17.8M Sell
107,672
-6,256
-5% -$1.08M 0.3% 88
2018
Q3
$22M Sell
113,928
-18,638
-14% -$3.32M 0.38% 66
2018
Q2
$22.5M Sell
132,566
-577
-0.4% -$89.4K 0.43% 57
2018
Q1
$21.7M Buy
133,143
+16,991
+15% +$2.78M 0.43% 56
2017
Q4
$17.4M Buy
116,152
+40,100
+53% +$5.94M 0.4% 64
2017
Q3
$11.6M Buy
76,052
+42,281
+125% +$6.36M 0.25% 99
2017
Q2
$4.35M Sell
33,771
-17,855
-35% -$2.15M 0.1% 297
2017
Q1
$5.65M Sell
51,626
-1,563
-3% -$138K 0.05% 403
2016
Q4
$4.33M Buy
53,189
+3,000
+6% +$244K 0.04% 397
2016
Q3
$4.38M Buy
50,189
+2,986
+6% +$282K 0.05% 370
2016
Q2
$4.06M Buy
47,203
+16,187
+52% +$1.4M 0.04% 403
2016
Q1
$2.47M Buy
31,016
+20,415
+193% +$1.85M 0.03% 438
2015
Q4
$1.33M Sell
10,601
-26,919
-72% -$3.25M 0.01% 529
2015
Q3
$3.91M Buy
37,520
+4,119
+12% +$529K 0.04% 347
2015
Q2
$4.12M Sell
33,401
-4,097
-11% -$516K 0.04% 332
2015
Q1
$5.15M Buy
37,498
+664
+2% +$79.6K 0.04% 359
2014
Q4
$4.38M Sell
36,834
-1,300
-3% -$146K 0.04% 389
2014
Q3
$4.28M Buy
38,134
+22,500
+144% +$2.14M 0.04% 371
2014
Q2
$1.48M Sell
15,634
-128
-0.8% -$8.98K 0.01% 547
2014
Q1
$1.11M Sell
15,762
-59,300
-79% -$4.7M 0.01% 550
2013
Q4
$5.58M Buy
75,062
+61,551
+456% +$4.29M 0.06% 285
2013
Q3
$1.02M Sell
13,511
-1,528
-10% -$122K 0.01% 560
2013
Q2
$1.07M Buy
+15,039
New +$1.11M 0.02% 539

Other funds holding VRTX

Westpac Banking Corp's VRTX Position: Q2 2026 in Review

Westpac Banking Corp increased its Vertex Pharmaceuticals (VRTX) stake by 3.4% in Q2 2026, buying an estimated $37.7K and bringing the position to 2,614 shares worth $1.3M. The position accounts for 0.08% of the portfolio, ranked #194.

Westpac Banking Corp first reported a position in VRTX in Q2 2013 and has held it in 53 quarters since. The position peaked at $22.5M in Q2 2018. 1,749 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Westpac Banking Corp held 2,614 shares of Vertex Pharmaceuticals worth $1.3M as of Q2 2026.
  • Westpac Banking Corp bought 85 Vertex Pharmaceuticals shares in Q2 2026, an estimated $37.7K.
  • Vertex Pharmaceuticals made up 0.08% of Westpac Banking Corp's portfolio in Q2 2026, its #194 holding.
  • Westpac Banking Corp first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
  • Westpac Banking Corp's Vertex Pharmaceuticals position peaked at $22.5M in Q2 2018.
  • 1,749 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Westpac Banking Corp's 13F filing for Q2 2026, filed 12 Aug 2026.